In swine production, water medication lines handle the hydroxy ester veterinary grade API as a soluble granulate rather than as a raw micronized powder, because direct powder addition to drinking water tends to produce wetting failures at drinker nipple valves under line pressures between 1.5 bar and 3.0 bar. The conversion step is normally high-shear pre-blending followed by fluid-bed granulation with a carrier system of lactose monohydrate and povidone K30; in field-scale mixers, the wet mass is ejected at impeller tip speeds between 5 m/s and 8 m/s and then transferred to a fluid-bed dryer with inlet air temperature held between 55 °C and 65 °C. Product moisture is lowered to < 2.0 % by Karl Fischer titration under USP <921> Method Ic before sifting over an 80-mesh screen. Addition levels for the hydroxy ester in the granule concentrate screened during production campaigns generally fall within 0.5 wt% to 2.0 wt%, with final drinking-water concentration adjusted by the veterinarian according to approved species-specific label dose; the upper addition ratio in raw concentrate is constrained by dissolution-mixing time, which rises sharply above 2.5 wt% in hard water with total hardness exceeding 300 mg/L CaCO₃. Use of sequestrants such as citric acid at 0.05 wt% to 0.10 wt% is therefore embedded in the dry blend. Compliance is anchored to Regulation (EU) 2019/6 and to VICH GL1 for analytical procedure validation; residual solvent testing follows VICH GL18 with Class 2 solvent limits applied to the granulation solvent. Terminal finished product types include 250 g and 1 kg water-soluble sachets, bulk oral powders for proportional dosing pumps, and pre-weighed granules for medication tanks.

Does Terminal Sterilisation of Hydroxy Ester Injectable Solutions Require Inert Gassing?

Aqueous injectable presentation of the hydroxy ester veterinary grade API is constrained less by sterile filtration throughput than by the hydrolytic susceptibility of the ester linkage when the bulk solution is held above 40 °C under alkaline pH. In aseptic filling suites, the active is dissolved at 1.0 % w/v to 5.0 % w/v in Water for Injections, with propylene glycol or glycerol co-solvent levels between 20 % and 40 % and a citrate/phosphate buffer holding pH at 4.5–6.0. The compounding vessel is blanketed with nitrogen, and dissolved oxygen is reduced to below 0.5 mg/L before sterile filtration through 0.22 µm polyethersulfone membrane. Terminal moist-heat sterilisation at 121 °C for 15 min is generally avoided because the ester bond is progressively hydrolysed in comparative production runs; when a terminal cycle is unavoidable, the solution is limited to 100 mL containers with a post-cycle pH drift specification of not more than 0.3 units. Sterility assurance follows Ph. Eur. 5.1.1 and USP <71>; container closure integrity is verified to USP <1207>. Addition ratios are expressed on the free-acid equivalent rather than on the salt form to prevent overcompensation when the hydrochloride or sodium salt is used. Published accelerated stability data for this specific hydroxy ester configuration is limited, so each formulation change requires ester hydrolysis screening by stress testing at pH 2.0, 6.5 and 8.0 under VICH GL11 thermal conditions. Finished terminal product types include 50 mL and 100 mL multi-dose vials for cattle and sheep, with benzyl alcohol preserved at 1.5 % v/v in the multi-dose presentation.

When oral dosing across large ruminant herds is required, the hydroxy ester veterinary grade API is supplied as a non-sterile liquid drench rather than as a feed admixture because individual animal dosing permits precise weight-banded administration. The vehicle is compounded with propylene glycol and glycerol to a final viscosity between 40 mPa·s and 80 mPa·s at 20 °C; the hydroxy ester is dissolved at 2.5 % w/v to 5.0 % w/v, with the working pH adjusted to 5.5–6.5 using citrate buffer. Production-scale batches are mixed in a rotor-stator homogeniser at 3000 rpm for 15 min to 20 min under vacuum to limit aeration. The solution is then passed through a 5 µm polypropylene depth filter before filling into pre-rinsed containers. Ester hydrolysis at the low-alcohol end of the formulation has been observed during prolonged storage above 30 °C, so the stability protocol includes VICH GL11 intermediate storage at 30 °C/65 % RH with potency and related-substance monitoring against Ph. Eur. 2.2.29 liquid chromatography. Compliance for the finished veterinary product is under Regulation (EU) 2019/6; the fill line and cleaning validation follow the principles of EU GMP Annex 15 for non-sterile liquids. Terminal product types include 1 L hDPE drench bottles, 5 L backpack packs and 10 L farm-dispensing containers, with graduated dosing chambers marked in 0.5 mL increments.

Direct Compression Fails If Blending Time Exceeds the Lubricant’s Shear Stability Window

For companion-animal dose titration, the tablet route exposes the hydroxy ester veterinary grade API to dry-mixing shear that can depress hardness if lubrication is prolonged. The raw material is typically pre-sieved over 60-mesh and dry-blended with microcrystalline cellulose, lactose monohydrate and crospovidone before lubrication with magnesium stearate at 0.5 wt% for not more than 5 min; extended lubrication above 20 min depresses tablet hardness due to shear-induced surface coating. The active addition ratio in the tablet core is set between 5.0 wt% and 10.0 wt% for finished strengths of 25 mg and 50 mg per tablet, with direct compression on a rotary press at 8 kN to 15 kN compression force. Target hardness is 60 N to 100 N, friability below 1.0 % per Ph. Eur. 2.9.7, disintegration below 15 min by USP <701> in 0.1 N HCl. Uniformity of dosage units is verified to USP <905> and content homogeneity to Ph. Eur. 2.9.6. The ester functionality is sensitive to basic fillers; the formulation therefore excludes calcium carbonate and sodium bicarbonate. For production-scale behaviour, batch-to-batch particle-size variation in the API has been a greater source of segregation than press speed variation, so the API is pre-milled to d₁₀ 10 µm, d₅₀ 60 µm and d₉₀ 120 µm before blending. Terminal finished dosage forms include non-scored 25 mg tablets, scored 50 mg tablets and press-fit 100 mg tablets for canine use, packaged in cold-form aluminium/aluminium blisters to limit moisture ingress below 0.6 % water activity.

Poultry Premix Dilution, Pelleting and Moisture Thresholds

Premix manufacture for poultry imposes a narrower processing window than oral powders because the hydroxy ester veterinary grade API is exposed to both mechanical blending and conditioning steam before pelleting. Production masterbatches are diluted stepwise from an active loading of 2.0 % w/w down to 0.5 % w/w using a calcium carbonate/lactose carrier; each dilution step is mixed in a double-ribbon blender for 20 min at 25 rpm. The final complete-feed inclusion is set by the approved label, typically in the range 50 mg/kg to 200 mg/kg. At the feed mill, the premix is introduced into the mixer after major ingredients and before added fat; this sequence reduces hydrophobic competition between the ester and lipid phases. Pelleting processes are limited to conditioning temperatures at or below 70 °C and post-pelleting moisture below 13.0 %, because ester hydrolysis accelerates in high-moisture steam and the resulting potency loss has been observed in production batches run above 80 °C. Compliance is split between feed hygiene requirements in Regulation (EC) No 183/2005/EC, maximum undesirable substance limits in Directive 2002/32/EC, and veterinary premix authorisation under Regulation (EU) 2019/6. Residual solvent and homogeneity testing follow VICH GL18 and Ph. Eur. 2.9.6. Terminal finished product types include 5 kg, 20 kg and 25 kg multi-layer paper premix bags with inner polyethylene liners, and bulk tote bags for integrated feed mills.

Hard gelatin capsule operations handling the hydroxy ester veterinary grade API require a pre-granulated flowable fill rather than direct encapsulation of micronized powder, because the raw powder exhibits cohesive flow behaviour at particle sizes below 20 µm. The API is wet-granulated with lactose monohydrate and povidone K30 and dried to residual moisture < 2.0 % before blending with sodium starch glycolate at 2.0 wt% to 5.0 wt% and magnesium stearate at 0.5 wt%. The active addition ratio in the granule fill is from 4.0 wt% to 8.0 wt%, allowing encapsulated strengths of 100 mg, 250 mg and 500 mg in size 1, size 0 and size 00 hard gelatin capsules. Capsule filling is carried out on an auger-type or dosator-type machine at 60–80 % target fill weight, with weight variation governed by USP <905> and dissolution checked by USP <711> apparatus 2 at 50 rpm in 900 mL of 0.1 N HCl. Because hydroxy ester migration within the capsule can be induced by low-density fillers, the formulation excludes talc above 1.0 % and uses pregelatinised starch to improve homogeneity. Stability protocols include VICH GL11 zones II and IV conditions; capsule shells are packed with desiccant to maintain internal relative humidity below 40 %. Terminal finished product types include oral capsules for canine and equine use, hospital unit-dose capsules for veterinary pharmacies, and clinical trial capsule kits with bar-coded primary packaging.